We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other stocks under $5 with biggest upside potential. On January 20, Bloomberg reported that ...

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.